Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Sorafenib.

Brian I Rini1

  • 1Department of Solid Tumour Oncology, Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA. rinib2@ccf.org

Expert Opinion on Pharmacotherapy
|March 1, 2006
PubMed
Summary
This summary is machine-generated.

Sorafenib, a kinase inhibitor, shows anti-tumor effects in metastatic renal cell carcinoma by targeting tumor proliferation and angiogenesis. It delays disease progression and is generally well-tolerated, warranting further investigation in various cancers.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Casdatifan shows durable response linked to HIF-2α biology in kidney cancer.

Nature·2026
Same author

Podcast on the Emerging Role of PD-(L)1/VEGF Bispecific Antibodies in the Evolving Advanced Renal Cell Carcinoma Treatment Landscape.

Oncology and therapy·2026
Same author

Comprehensive Genomic and Transcriptomic Characterization of Matched Primary and Recurrent Tumors in High-risk Localized Renal Cell Carcinoma.

European urology·2026
Same author

Cardiac biomarkers in patients with renal cell carcinoma treated with immune checkpoint inhibitors.

The oncologist·2026
Same author

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of renal cell carcinoma, version 3.0.

Journal for immunotherapy of cancer·2026
Same author

Reconsidering adjuvant and perioperative immune-checkpoint inhibition: de-escalation, expansion and personalization.

Nature reviews. Clinical oncology·2026
Same journal

Pharmacotherapeutic interventions for pediatric ulcerative colitis.

Expert opinion on pharmacotherapy·2026
Same journal

The rise and fall of TRPV1-targeted analgesia in osteoarthritis: a critical appraisal.

Expert opinion on pharmacotherapy·2026
Same journal

Dopamine transporter and beyond: evolving targets and combination strategies in stimulant use disorder.

Expert opinion on pharmacotherapy·2026
Same journal

GnRH antagonists for the treatment of fibroids and adenomyosis, current evidence and future perspectives.

Expert opinion on pharmacotherapy·2026
Same journal

Pharmacotherapeutic strategies for the management of congenital adrenal hyperplasia.

Expert opinion on pharmacotherapy·2026
Same journal

Current advances in pharmacotherapeutic strategies for the treatment of complicated intra-abdominal infections.

Expert opinion on pharmacotherapy·2026
See all related articles

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Sorafenib is a small molecule kinase inhibitor.
  • It targets kinases involved in tumor proliferation and angiogenesis, such as Raf and VEGFR.
  • VEGF-targeting agents have shown anti-tumor effects in metastatic renal cell carcinoma.

Purpose of the Study:

  • To evaluate the anti-tumor effects of Sorafenib.
  • To assess its efficacy in delaying disease progression in metastatic renal cell carcinoma.
  • To investigate its tolerability and safety profile.

Main Methods:

  • Pharmacodynamic studies to confirm Raf kinase inhibition in vivo.
  • Clinical trials in patients with metastatic renal cell carcinoma.
  • Monitoring of adverse events and toxicities.

Related Experiment Videos

Main Results:

  • Sorafenib demonstrated substantial anti-tumor effects in metastatic renal cell carcinoma.
  • A delay in time to disease progression was observed in cytokine-refractory metastatic renal cell carcinoma.
  • Sorafenib was well-tolerated, with common toxicities including rash, diarrhea, hand-foot skin reaction, fatigue, and hypertension.

Conclusions:

  • Sorafenib is an effective treatment for metastatic renal cell carcinoma, delaying disease progression.
  • The drug is generally well-tolerated, with manageable side effects.
  • Further investigation in diverse tumor types is ongoing.